<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="116140">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02102568</url>
  </required_header>
  <id_info>
    <org_study_id>2013-A01284-41</org_study_id>
    <nct_id>NCT02102568</nct_id>
  </id_info>
  <brief_title>Study the Impact of Chemo-induced Menopause on the Quality of Life in Young Women of Childbearing Age and Diagnosed With Non-metastatic Breast Cancer</brief_title>
  <acronym>menocor</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Jean Perrin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Jean Perrin</source>
  <oversight_info>
    <authority>France: ANSM-Agence Nationale de Securite du medicament</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective multicenter study, Out Health Products that evaluates to 2 years the impact of
      chemo-induced menopause (MCI) on the functional score of quality of life questionnaire
      QLQ-C30 in young women age childbearing and living with breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Evaluation of the 2-year impact of chemo-induced menopause (MCI) on the functional score of quality of life questionnaire QLQ-C30 in young women of childbearing age and diagnosed with breast cancer.</measure>
    <time_frame>until 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the rate of MCI after chemotherapy</measure>
    <time_frame>until 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and Specificity of Anti-Mullerian Hormone blood AMH in the prediction of MCI</measure>
    <time_frame>until 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive value of amenorrhea 6 months to 2 years of menopause</measure>
    <time_frame>until 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of change in FSH (Follicle Stimulating Hormone) and estradiol before chemotherapy and at the end of chemotherapy</measure>
    <time_frame>until 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of MCI on specific aspects of quality of life (anxiety, depression, body image, sporting activity and quality of sleep) after breast cancer</measure>
    <time_frame>until 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>BREAST CANCER</condition>
  <arm_group>
    <arm_group_label>diagnostic</arm_group_label>
    <description>quality of life score and dosage</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        premenopausal women with age between 18 to 45 years. premenopausal women with breast
        cancer non metastatic.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient aged over 18 and under 45

          -  Patient without amenorrhea at diagnosis

          -  Performance status 2 (according to WHO criteria )

          -  Patient diagnosed with histologically proven breast cancer , non metastatic Clinical
             Stages I , IIA , IIB and IIIA

          -  Positive Hormone Receptors (defined by a rate of 10% of labeled cells and
             immunohistochemistry (IHC) ) or negative

          -  Status HER2 positive or HER2 negative ( defined a score of 0 or 1 + by IHC , or a 2 +
             score by IHC and FISH / ISHS / CISH negative)

          -  Patients treated with neoadjuvant or adjuvant chemotherapy hematological, renal and
             hepatic functions satisfying : ANC&gt; 2,109 / L, platelets &gt; 100 . 109 / L, Hb&gt; 10 g /
             dl , normal bilirubin, AST and ALT &lt;2.5 upper normal value ( VNS) , alkaline
             phosphatase &lt;2.5 VSN , creatinine clearance &gt; 60 ml / min

          -  Obtaining informed consent in writing, signed and dated

          -  Affiliation Social Security system (or be the beneficiary of such a plan ) under the
             terms of the Act of August 9, 2004

        Exclusion Criteria:

          -  Patient male

          -  Cancer metastatic

          -  Any tumor T4 ( skin invasion , deep grip, inflammatory breast cancer )

          -  Patient who underwent surgical castration of ovariectomy type hysterectomy or tubal
             ligation

          -  Please have endometriosis

          -  Please pregnant or nursing

          -  Please not using effective contraception

          -  Patient who have had hormone therapy or chemotherapy

          -  Patient who have already taken similar Gn -RH or LH -RH (chemical castration)

          -  Patient whose mother was early menopause without treatment

          -  Presence of comorbidities related to fertility or medical history related to
             fertility ovarian failure types or sterility

          -  significant neurological or psychiatric abnormalities

          -  Inability of the patient to complete the questionnaires ( the language barrier )

          -  Private Patient freedom by court or administrative

          -  Patient with another pathology deemed incompatible with the input of the patient in
             the protocol

          -  Participation in another clinical trial involving the chemical or surgical castration
             of the patient

          -  Please geographically unstable in the next 6 months or residing away from the
             treatment center and thereby making it difficult to monitor
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joyce DOHOU</last_name>
    <phone>0033463663337</phone>
    <email>joyce.dohou@cjp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Jean PERRIN</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce DOHOU</last_name>
      <phone>0033463663337</phone>
    </contact>
    <investigator>
      <last_name>Marie-Ange MOURET-REYNIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Emile Roux</name>
      <address>
        <city>Le puy-en Velay</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joyce DOHOU</last_name>
      <phone>0033463663337</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>JOYCE DOHOU</last_name>
      <phone>0033463663337</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Lucien Neuwirth</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joyce DOHOU</last_name>
      <phone>0033463663337</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>May 5, 2014</lastchanged_date>
  <firstreceived_date>March 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
